0000000000341862

AUTHOR

M. Giordano

showing 3 related works from this author

Influence of comorbidity and cognitive status on instrumental activities of daily living in amnestic mild cognitive impairment: results from the ReGA…

2007

Objectives To investigate whether amnestic mild cognitive impairment (aMCI) is characterised by restriction in instrumental activities of daily living (IADL). Further, to examine the role of comorbidity and cognitive performance on IADL changes in aMCI subjects. Methods The study included 132 subjects with aMCI and 249 subjects with no cognitive impairment (NCI), consecutively enrolled as outpatients in a multicentric Italian clinical-based study, the ReGAl Project. All subjects underwent a comprehensive evaluation including clinical examination, laboratory screening, neuroimaging and cognitive and behavioral assessments. Functional status was evaluated by the Lawton's Instrumental Activiti…

GerontologyMalemedicine.medical_specialtyActivities of daily livingSettore MED/25 - PSCHIATRIAComorbidityNeuropsychological Testsbehavioral disciplines and activitiesDisability EvaluationMental ProcessesRating scaleExecutive functionmental disordersmedicine80 and overHumansEffects of sleep deprivation on cognitive performanceCognitive performanceAgedGeriatricsCognitive evaluation theoryAged 80 and overDepressive DisorderCognitive disorderActivities of daily livingMild cognitive impairmentCognitionmedicine.diseaseComorbidityActivities of daily living; Cognitive performance; Comorbidity; Executive function; Mild cognitive impairment; Activities of Daily Living; Aged; Aged 80 and over; Amnesia; Comorbidity; Depressive Disorder; Disability Evaluation; Female; Humans; Male; Mental Processes; Neuropsychological Tests; Geriatrics and Gerontology; Psychiatry and Mental HealthPsychiatry and Mental HealthSettore MED/26 - NeurologiaFemaleactivities of the day livingAmnesiaGeriatrics and GerontologyPsychologyhuman activities
researchProduct

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patient…

2020

<b><i>Background:</i></b> Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. <b><i>Methods:</i></b> For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). <b><i>Res…

Oncologymedicine.medical_specialtymedicine.drug_classPopulationAnastrozoleNOInternal medicineFulvestrant · First-line setting · Hormone receptor positive Advanced breast cancermedicineAdjuvant therapyProgression-free survivaleducationFulvestrantFirst-Line settingeducation.field_of_studyHormone receptor positiveAromatase inhibitorFulvestrantEVAbusiness.industrytrialsCancerEndocrine TherapyGIM-13medicine.diseaseEndocrine Therapy HR+/HER2– Advanced Breast Cancer High-Dose Fulvestrant First-Line setting EVA GIM-13 AMBRA trialsAdvanced breast cancer; First-line setting; Fulvestrant; Hormone receptor positiveOncologyHR+/HER2–Advanced Breast CancerSurgeryAMBRAbusinessHigh-DoseTamoxifenResearch Articlemedicine.drug
researchProduct

Low bcl-2 expression and increased spontaneous apoptosis in T-lymphocytes from newly-diagnosed IDDM patients.

1995

The bcl-2 gene product has been shown to regulate apoptotic cell death, and its dysregulation has been shown to induce several abnormalities in the immune system. No data exist regarding bcl-2 expression in autoimmune diseases, such as human insulin-dependent diabetes mellitus (IDDM). We investigated bcl-2 protein expression by testing T lymphocytes from 15 newly-diagnosed (3 weeks) IDDM patients in comparison to 10 age-matched control subjects. The expression of bcl-2 on CD3+ lymphocyte subsets was investigated after membrane permeabilization by two- or three-colour immunofluorescence. When the percentage and mean fluorescence intensity (MFI) of bcl-2+/CD3+ cells from normal individuals an…

AdultBlood GlucoseMaleProgrammed cell deathmedicine.medical_specialtyAdolescentCD3 ComplexEndocrinology Diabetes and MetabolismLymphocyteCD3T-LymphocytesGene ExpressionApoptosisBiologychemistry.chemical_compoundImmune systemAntigens CDReference ValuesRisk FactorsT-Lymphocyte SubsetsInternal medicineProto-Oncogene ProteinsInternal MedicinemedicineHumansFamilyPropidium iodideAutoantibodiesAutoimmune diseaseGlycated HemoglobinT lymphocytemedicine.diseaseFlow Cytometrymedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1chemistryProto-Oncogene Proteins c-bcl-2ApoptosisCase-Control Studiesbiology.proteinFemaleDiabetologia
researchProduct